RHA Redensity - Perioral Rhytids

NACompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

December 17, 2017

Study Completion Date

January 8, 2019

Conditions
Perioral RhytidsAgingWrinkle
Interventions
DEVICE

TEOSYAL RHA Redensity

A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.

Trial Locations (8)

Unknown

Beverly Hills

Santa Monica

Coral Gables

Omaha

High Point

Fairfax

Montreal

Victoria

All Listed Sponsors
lead

Teoxane SA

INDUSTRY

NCT03092219 - RHA Redensity - Perioral Rhytids | Biotech Hunter | Biotech Hunter